Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an announcement.
Cosmo Pharmaceuticals has published the agenda for its General Meeting 2025, scheduled for May 30 in Amsterdam. Key items include the approval of the 2024 annual report, a proposal to distribute 2.05 EUR per share from reserves, and the election of board members. This meeting is a platform for reviewing achievements, discussing priorities, and engaging with shareholders, reflecting the company’s commitment to transparency and stakeholder engagement.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on revolutionizing healthcare through innovative products that address unmet needs. The company operates in Healthtech/AI, Dermatology, Gastroenterology, and contract manufacturing and development. It collaborates with global partners like Medtronic and Sun Pharma and has a presence in Dublin, San Diego, and Italy, employing around 330 people.
YTD Price Performance: -25.38%
Average Trading Volume: 542
Technical Sentiment Signal: Buy
Current Market Cap: CHF802.3M
Learn more about COPN stock on TipRanks’ Stock Analysis page.